About Us  |  Contact Us  |  Español
VNA of Care New England
VNA of Care New England

FDA Approves Mekinist Plus Tafinlar for Late-Stage Melanoma

Newly approved for people who have certain mutations in the BRAF V600E and V600K genes
FRIDAY, Jan. 10, 2014 (HealthDay News) -- The U.S. Food and Drug Administration has approved Mekinist for use with another drug, Tafinlar, to treat advanced melanoma that is metastatic or unresectable.
Mekinist is newly approved to be used in combination with Tafinlar (dabrafenib). Both drugs were first sanctioned in May 2013 to be used by themselves to battle advanced melanoma, the agency said. The combination therapy is newly approved for people who have certain mutations in the BRAF V600E and V600K genes, the FDA said. About half of melanoma cases have the mutated genes.
The combination therapy was clinically evaluated in 162 people. Of those treated, 78 percent had their cancer shrink or disappear for an average of 10.5 months, the agency said.
The most common side effects included fever, chills, rash, fatigue, nausea, diarrhea, abdominal pain, and peripheral edema. More serious adverse reactions included bleeding, blood clots, heart failure, and skin and eye problems. The drug combination can cause infertility and birth defects, the agency said, warning men and women of child-bearing age.
Both drugs are marketed by GlaxoSmithKline, based in Research Triangle Park, N.C.
More Information (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm381159.htm )
Health Headlines
If Kids Think Someone's Watching, They're More Likely to Wash Their HandsView in a lightbox
Spring Cleaning Safety TipsView in a lightbox
Ragwitek Approved for Adult Ragweed AllergyView in a lightbox
Restaurants in Poor Areas Push Unhealthy Foods, Study FindsView in a lightbox
Certain Sedatives Tied to Breathing Problems in Older COPD PatientsView in a lightbox
VNA of Care New England
© 2011 Site Index | Disclaimer | Legal Notices